Calcimedica reports first quarter 2024 financial results and provides clinical & corporate updates

Last patient enrolled in carpo, phase 2b trial of auxora™ in acute pancreatitis (ap); topline data expected in 2q 2024 kourage, phase 2 trial in severe acute kidney injury (aki) remains on track to initiate patient enrollment in 2q 2024 with data expected in 2025 collaborators from cedars-sinai to present abstract on human proteomics data supporting the potential benefits of auxora in ap at digestive disease week (ddw) 2024 cash position expected to fund operations into 2h 2025 la jolla, calif. , may 13, 2024 /prnewswire/ -- calcimedica inc. ("calcimedica") (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the first quarter ended march 31, 2024.
CALC Ratings Summary
CALC Quant Ranking